Fitness Trends Anti-body Coupled T Receptor Therapy Market

Anti-body Coupled T Receptor Therapy Market -
Global Industry Insights, Trends, Outlook and
Opportunity Analysis 2018-2026
Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in
which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T
receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor,
multiplying it in lab and then administering it along with targeting antibodies. The advantage
in this approach is, that these T cells do not attack normal antigens from blood circulation but
attack only antigens attached to the cancerous cells. This is possible as tumor specific
monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost effective as
it can be used in various cancer therapy. Also, greater therapeutic benefit with minimum side
effects can be possible by adjusting the amount of targeting antibody which is essential for
activation of the ACTR T cells.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1600
Rising incidence of cancer and new products to be launched in future to drive the market for
anti-body coupled T receptor therapy market.
According to World Health Organization (WHO), cancer is one of the leading non-communicable
disease and second leading cause of death globally. As reported by International Agency for
Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and
32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and
Lymphoma Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual
new cases of lymphoma. Therefore, such high number of cancer patient would propel the anti-
body coupled T receptor therapy market.
ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as
CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead
Lifescience, Inc.) has side effects such as cytokine release syndrome, and neurological toxicity as
discussed in their respective product literatures and other studies. ACTR therapy being specific